Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More The Motley Fool 23:12 Sat, 24 Oct
Gene therapy offers to beat hepatitis B virus by muting its DNA The Hindu 4d DNA Global Health Genetics Article paywall All sources
Casgevy gains UK label expansion for younger patient population Pharmaceutical Technology 2d CRISPR Therapeutics Sickle Cell Disease Pharma All sources
CRISPR prime editing rewrites DNA in the human body for the first time Singularity Hub 3d DNA Genetics Biology All sources
Custom gene-Editing therapies for rare diseases could win faster approvals under FDA draft plan, not yet final Medical Daily 2d FDA Pennsylvania Rare Diseases
Acumen’s Alzheimer’s drug fails in phase II; stock plummets BioWorld 2d Alzheimer's Health Article paywall
Philips launches HyperVue Integrated System in the U.S., bringing advanced coronary imaging and physiology into the cathlab Toronto Star 2d Consumer Electronics Philips Electronics
Anthropic acquires biotech startup exploring AI-led drug development European Pharmaceutical Review 3d Biotech Anthropic AI
